PLN 79.8
(4.04%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 2.26 Million PLN | -9.35% |
2022 | 2.5 Million PLN | 13.93% |
2021 | 2.19 Million PLN | 48.44% |
2020 | 1.47 Million PLN | 11.81% |
2019 | 1.32 Million PLN | -23.41% |
2018 | 1.72 Million PLN | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 3.26 Million PLN | 43.93% |
2024 Q2 | 7.11 Million PLN | 118.06% |
2023 FY | 2.26 Million PLN | -9.35% |
2023 Q1 | 1.98 Million PLN | -20.55% |
2023 Q4 | 2.26 Million PLN | -15.85% |
2023 Q3 | 2.69 Million PLN | 68.69% |
2023 Q2 | 1.59 Million PLN | -19.63% |
2022 Q4 | 2.5 Million PLN | 19.73% |
2022 Q2 | 2.05 Million PLN | 1.34% |
2022 Q1 | 2.03 Million PLN | -4.84% |
2022 Q3 | 2.09 Million PLN | 1.47% |
2021 Q3 | 2.22 Million PLN | 0.0% |
2021 Q4 | 2.13 Million PLN | -3.99% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
BIOTON S.A. | 215.86 Million PLN | 98.949% |
Captor Therapeutics Spolka Akcyjna | 28.07 Million PLN | 91.919% |
Mabion S.A. | 90.47 Million PLN | 97.493% |
Molecure S.A. | 11.34 Million PLN | 80.003% |
NanoGroup S.A. | 1.49 Million PLN | -52.244% |
Pharmena S.A. | 1.9 Million PLN | -19.023% |
Poltreg S.A. | 39.58 Million PLN | 94.269% |
Pure Biologics Spólka Akcyjna | 20.84 Million PLN | 89.117% |
Ryvu Therapeutics S.A. | 120.36 Million PLN | 98.115% |
Synthaverse S.A. | 153.26 Million PLN | 98.52% |
Urteste S.A. | 1.85 Million PLN | -22.295% |